{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:42:35Z","timestamp":1793727755525,"version":"4.6.1"},"reference-count":60,"publisher":"American Society of Hematology","issue":"16","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,18]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Autologous stem cell transplantation (ASCT) is the standard of care consolidation therapy for eligible patients with myeloma but most patients eventually progress, an event associated with features of immune escape. Novel approaches to enhance antimyeloma immunity after ASCT represent a major unmet need. Here, we demonstrate that patient-mobilized stem cell grafts contain high numbers of effector CD8 T cells and immunosuppressive regulatory T cells (Tregs). We showed that bone marrow (BM)-residing T cells are efficiently mobilized during stem cell mobilization (SCM) and hypothesized that mobilized and highly suppressive BM-derived Tregs might limit antimyeloma immunity during SCM. Thus, we performed ASCT in a preclinical myeloma model with or without stringent Treg depletion during SCM. Treg depletion generated SCM grafts containing polyfunctional CD8 T effector memory cells, which dramatically enhanced myeloma control after ASCT. Thus, we explored clinically tractable translational approaches to mimic this scenario. Antibody-based approaches resulted in only partial Treg depletion and were inadequate to recapitulate this effect. In contrast, a synthetic interleukin-2 (IL-2)\/IL-15 mimetic that stimulates the IL-2 receptor on CD8 T cells without binding to the high-affinity IL-2Ra used by Tregs efficiently expanded polyfunctional CD8 T cells in mobilized grafts and protected recipients from myeloma progression after ASCT. We confirmed that Treg depletion during stem cell mobilization can mitigate constraints on tumor immunity and result in profound myeloma control after ASCT. Direct and selective cytokine signaling of CD8 T cells can recapitulate this effect and represent a clinically testable strategy to improve responses after ASCT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023022000","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T21:01:40Z","timestamp":1706734900000},"page":"1656-1669","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation"],"prefix":"10.1182","volume":"143","author":[{"given":"Shuichiro","family":"Takahashi","sequence":"first","affiliation":[{"name":"1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone A.","family":"Minnie","sequence":"additional","affiliation":[{"name":"1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen S.","family":"Ensbey","sequence":"additional","affiliation":[{"name":"1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2051-0825","authenticated-orcid":false,"given":"Christine R.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel R. W.","family":"Legg","sequence":"additional","affiliation":[{"name":"1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Koyama","sequence":"additional","affiliation":[{"name":"1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart D.","family":"Olver","sequence":"additional","affiliation":[{"name":"2QIMR Berghofer Medical Research Institute, Herston, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alika D.","family":"Collinge","sequence":"additional","affiliation":[{"name":"2QIMR Berghofer Medical Research Institute, Herston, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Keshmiri","sequence":"additional","affiliation":[{"name":"1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Comstock","sequence":"additional","affiliation":[{"name":"1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3437-9659","authenticated-orcid":false,"given":"Antiopi","family":"Varelias","sequence":"additional","affiliation":[{"name":"2QIMR Berghofer Medical Research Institute, Herston, QLD, Australia"},{"name":"3Faculty of Medicine, University of Queensland, St Lucia, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian J.","family":"Green","sequence":"additional","affiliation":[{"name":"1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"4Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey R.","family":"Hill","sequence":"additional","affiliation":[{"name":"1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"4Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2024041815204022500_bib1","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"2","key":"2024041815204022500_bib2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2024041815204022500_bib3","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"2024041815204022500_bib4","doi-asserted-by":"crossref","first-page":"651288","DOI":"10.3389\/fimmu.2021.651288","article-title":"Autologous stem cell transplantation for myeloma: cytoreduction or an immunotherapy?","volume":"12","author":"Minnie","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"2024041815204022500_bib5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2024041815204022500_bib6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"issue":"16","key":"2024041815204022500_bib7","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2018-01-825240","article-title":"Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT\u00a0blockade","volume":"132","author":"Minnie","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2024041815204022500_bib8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1172\/JCI98888","article-title":"Bone marrow transplantation generates T cell-dependent control of myeloma in mice","volume":"129","author":"Vuckovic","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"2024041815204022500_bib9","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.bbmt.2018.06.023","article-title":"Differences in cellular composition of peripheral blood stem cell grafts from healthy stem cell donors mobilized with either granulocyte colony-stimulating factor (G-CSF) alone or G-CSF and plerixafor","volume":"24","author":"Teipel","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2024041815204022500_bib10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/blood-2009-11-256495","article-title":"Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma","volume":"116","author":"Hill","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2024041815204022500_bib11","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood.V88.8.3230.bloodjournal8883230","article-title":"An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin","volume":"88","author":"Cooke","year":"1996","journal-title":"Blood"},{"issue":"24","key":"2024041815204022500_bib12","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2024041815204022500_bib13","doi-asserted-by":"crossref","first-page":"e157907","DOI":"10.1172\/JCI157907","article-title":"TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice","volume":"133","author":"Minnie","year":"2023","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"2024041815204022500_bib14","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.4049\/jimmunol.1302315","article-title":"Modification of T cell responses by stem cell mobilization requires direct signaling of the T\u00a0cell by G-CSF and IL-10","volume":"192","author":"MacDonald","year":"2014","journal-title":"J\u00a0Immunol"},{"issue":"22","key":"2024041815204022500_bib15","doi-asserted-by":"crossref","first-page":"8451","DOI":"10.1158\/0008-5472.CAN-04-1987","article-title":"Bone marrow is a reservoir for CD4+CD25+ regulatory T\u00a0cells that traffic through CXCL12\/CXCR4 signals","volume":"64","author":"Zou","year":"2004","journal-title":"Cancer Res"},{"issue":"6","key":"2024041815204022500_bib16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","article-title":"Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor","volume":"30","author":"Miyara","year":"2009","journal-title":"Immunity"},{"issue":"9","key":"2024041815204022500_bib17","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ni831","article-title":"Cross-primed CD8(+) T cells mediate graft rejection via a distinct effector\u00a0pathway","volume":"3","author":"Valujskikh","year":"2002","journal-title":"Nat Immunol"},{"key":"2024041815204022500_bib18","doi-asserted-by":"crossref","first-page":"737880","DOI":"10.3389\/fcell.2021.737880","article-title":"Bone marrow regulatory T cells are a unique population, supported by niche-specific cytokines and plasmacytoid dendritic cells, and required for chronic graft-versus-host disease control","volume":"9","author":"Nicholls","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"22","key":"2024041815204022500_bib19","doi-asserted-by":"crossref","first-page":"e135681","DOI":"10.1172\/jci.insight.135681","article-title":"Bone marrow Tregs mediate stromal cell function and support hematopoiesis via IL-10","volume":"5","author":"Camacho","year":"2020","journal-title":"JCI Insight"},{"issue":"7466","key":"2024041815204022500_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature12428","article-title":"Stability and function of regulatory T cells is\u00a0maintained by a neuropilin-1-semaphorin-4a axis","volume":"501","author":"Delgoffe","year":"2013","journal-title":"Nature"},{"issue":"7738","key":"2024041815204022500_bib21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41586-018-0830-7","article-title":"De novo design of potent and selective mimics of IL-2 and IL-15","volume":"565","author":"Silva","year":"2019","journal-title":"Nature"},{"issue":"22","key":"2024041815204022500_bib22","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","article-title":"The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes","volume":"185","author":"Huang","year":"2022","journal-title":"Cell"},{"issue":"27","key":"2024041815204022500_bib23","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T\u00a0cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024041815204022500_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T\u00a0cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"issue":"11","key":"2024041815204022500_bib25","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"2024041815204022500_bib26","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1182\/blood-2002-09-2828","article-title":"Ex\u00a0vivo induction of multiple myeloma-specific cytotoxic T lymphocytes","volume":"102","author":"Hayashi","year":"2003","journal-title":"Blood"},{"issue":"9","key":"2024041815204022500_bib27","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood.V99.9.3280","article-title":"Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy","volume":"99","author":"Wen","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2024041815204022500_bib28","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1172\/JCI80445","article-title":"TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients","volume":"125","author":"Chauvin","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"2024041815204022500_bib29","doi-asserted-by":"crossref","first-page":"e002780","DOI":"10.1136\/jitc-2021-002780","article-title":"Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer","volume":"9","author":"Kim","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"3","key":"2024041815204022500_bib30","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.4049\/jimmunol.174.3.1269","article-title":"Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T\u00a0cells","volume":"174","author":"Becker","year":"2005","journal-title":"J\u00a0Immunol"},{"issue":"12","key":"2024041815204022500_bib31","doi-asserted-by":"crossref","first-page":"7654","DOI":"10.4049\/jimmunol.174.12.7654","article-title":"CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow","volume":"174","author":"Parretta","year":"2005","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"2024041815204022500_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"2024041815204022500_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.2008.18.7229","article-title":"Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer","volume":"27","author":"Salama","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"2024041815204022500_bib34","doi-asserted-by":"crossref","first-page":"15179","DOI":"10.1038\/srep15179","article-title":"Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci Rep"},{"issue":"10","key":"2024041815204022500_bib35","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2005-09-3671","article-title":"In\u00a0vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma","volume":"107","author":"Beyer","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2024041815204022500_bib36","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","article-title":"FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells","volume":"63","author":"Braga","year":"2014","journal-title":"Cancer Immunol Immunother"},{"issue":"13","key":"2024041815204022500_bib37","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-19-1714","article-title":"Marrow-infiltrating regulatory T cells correlate with the presence of dysfunctional CD4(+)PD-1(+) cells and inferior survival in patients with newly diagnosed multiple myeloma","volume":"26","author":"Alrasheed","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2024041815204022500_bib38","doi-asserted-by":"crossref","first-page":"8832","DOI":"10.1073\/pnas.132254399","article-title":"CD25+CD4+ T cells contribute to the control of memory CD8+ T\u00a0cells","volume":"99","author":"Murakami","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2024041815204022500_bib39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1172\/JCI19727","article-title":"CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism","volume":"113","author":"Dai","year":"2004","journal-title":"J\u00a0Clin Invest"},{"issue":"18","key":"2024041815204022500_bib40","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1073\/pnas.1103782108","article-title":"CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis","volume":"108","author":"McNally","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"2024041815204022500_bib41","doi-asserted-by":"crossref","first-page":"e86850","DOI":"10.1172\/jci.insight.86850","article-title":"Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease","volume":"1","author":"Le Texier","year":"2016","journal-title":"JCI Insight"},{"issue":"3","key":"2024041815204022500_bib42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.stem.2018.01.017","article-title":"CD150(high) bone marrow Tregs maintain hematopoietic stem cell quiescence and immune privilege via adenosine","volume":"22","author":"Hirata","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"6","key":"2024041815204022500_bib43","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cell.2017.05.005","article-title":"Interferon-gamma drives T(reg) fragility to promote anti-tumor immunity","volume":"169","author":"Overacre-Delgoffe","year":"2017","journal-title":"Cell"},{"issue":"5","key":"2024041815204022500_bib44","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2004-01-0328","article-title":"Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease","volume":"104","author":"Anderson","year":"2004","journal-title":"Blood"},{"issue":"24","key":"2024041815204022500_bib45","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/blood-2011-12-396119","article-title":"Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation","volume":"119","author":"Robb","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2024041815204022500_bib46","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.4049\/jimmunol.1301181","article-title":"Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in\u00a0vivo","volume":"191","author":"Zhang","year":"2013","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"2024041815204022500_bib47","doi-asserted-by":"crossref","first-page":"e000286","DOI":"10.1136\/jitc-2019-000286","article-title":"Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study","volume":"8","author":"Derman","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"9","key":"2024041815204022500_bib48","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"2024041815204022500_bib49","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/eji.200939613","article-title":"In\u00a0vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes","volume":"40","author":"Setiady","year":"2010","journal-title":"Eur J Immunol"},{"issue":"1","key":"2024041815204022500_bib50","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.immuni.2017.11.025","article-title":"Innate-like cytotoxic function of bystander-activated CD8(+) T cells is associated with liver injury in acute Hepatitis A","volume":"48","author":"Kim","year":"2018","journal-title":"Immunity"},{"key":"2024041815204022500_bib51","doi-asserted-by":"crossref","first-page":"102299","DOI":"10.1016\/j.coi.2023.102299","article-title":"Bystander activation in memory and antigen-inexperienced memory-like CD8 T cells","volume":"82","author":"Paprckova","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"2024041815204022500_bib52","doi-asserted-by":"crossref","first-page":"11291","DOI":"10.1038\/ncomms11291","article-title":"Virtual memory T cells develop and mediate bystander protective immunity in an IL-15-dependent manner","volume":"7","author":"White","year":"2016","journal-title":"Nat Commun"},{"issue":"5","key":"2024041815204022500_bib53","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"48","key":"2024041815204022500_bib54","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in\u00a0tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc Natl Acad Sci U\u00a0S A"},{"issue":"4","key":"2024041815204022500_bib55","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.1991.9.4.694","article-title":"Interleukin-2 toxicity","volume":"9","author":"Siegel","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"2024041815204022500_bib56","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024041815204022500_bib57","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1517\/14712598.6.12.1323","article-title":"Potential use of IL-2\/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease","volume":"6","author":"Boyman","year":"2006","journal-title":"Expert Opin Biol Ther"},{"issue":"26","key":"2024041815204022500_bib58","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024041815204022500_bib59","doi-asserted-by":"crossref","first-page":"104539","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A\u00a0systematic review of interleukin-2-based immunotherapies in\u00a0clinical trials for cancer and autoimmune diseases","volume":"90","author":"Raeber","year":"2023","journal-title":"EBioMedicine"},{"issue":"4","key":"2024041815204022500_bib60","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41587-022-01510-z","article-title":"A\u00a0split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy","volume":"41","author":"Quijano-Rubio","year":"2023","journal-title":"Nat Biotechnol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/16\/1656\/2222290\/blood_bld-2023-022000-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/16\/1656\/2222290\/blood_bld-2023-022000-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T15:21:07Z","timestamp":1713453667000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/16\/1656\/514793\/Regulatory-T-cells-suppress-myeloma-specific"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":60,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,4,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022000","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]}}}